Elanco Animal Health (ELAN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elanco Animal Health (ELAN) has a cash flow conversion efficiency ratio of 0.002x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($13.00 Million) by net assets ($6.50 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Elanco Animal Health (ELAN) financial flexibility to assess the company's free cash flow relative to its total liabilities.
Elanco Animal Health - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Elanco Animal Health's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market cap of Elanco Animal Health for the company's overall valuation and market capitalisation.
Elanco Animal Health Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elanco Animal Health ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EastGroup Properties Inc
NYSE:EGP
|
0.040x |
|
Kratos Defense & Security Solutions
NASDAQ:KTOS
|
-0.008x |
|
Gongniu Group Co Ltd
SHG:603195
|
0.084x |
|
Mankind Pharma Ltd
NSE:MANKIND
|
0.014x |
|
Formosa Chemicals & Fibre Corp
TW:1326
|
-0.004x |
|
Laurus Labs Limited
NSE:LAURUSLABS
|
0.222x |
|
Hyundai Heavy Industries Holdings Co Ltd
KO:267250
|
0.008x |
|
Mirae Asset Daewoo Securities Co Ltd
KO:006800
|
-0.323x |
Annual Cash Flow Conversion Efficiency for Elanco Animal Health (2016–2025)
The table below shows the annual cash flow conversion efficiency of Elanco Animal Health from 2016 to 2025. View latest Elanco Animal Health stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.55 Billion | $560.00 Million | 0.086x | -3.62% |
| 2024-12-31 | $6.10 Billion | $541.00 Million | 0.089x | +103.79% |
| 2023-12-31 | $6.22 Billion | $271.00 Million | 0.044x | -29.77% |
| 2022-12-31 | $7.29 Billion | $452.00 Million | 0.062x | -3.61% |
| 2021-12-31 | $7.51 Billion | $483.00 Million | 0.064x | +1429.93% |
| 2020-12-31 | $8.48 Billion | $-41.00 Million | -0.005x | -111.97% |
| 2019-12-31 | $5.55 Billion | $224.10 Million | 0.040x | -56.91% |
| 2018-12-31 | $5.20 Billion | $487.30 Million | 0.094x | +320.28% |
| 2017-12-31 | $7.79 Billion | $173.80 Million | 0.022x | +0.57% |
| 2016-12-31 | $7.03 Billion | $155.90 Million | 0.022x | -- |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide … Read more